IPSC vs. IVVD, NKTX, KNTE, FATE, BLUE, IMTX, MESO, HUMA, RLAY, and SRRK
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Invivyd (IVVD), Nkarta (NKTX), Kinnate Biopharma (KNTE), Fate Therapeutics (FATE), bluebird bio (BLUE), Immatics (IMTX), Mesoblast (MESO), Humacyte (HUMA), Relay Therapeutics (RLAY), and Scholar Rock (SRRK). These companies are all part of the "medical" sector.
Invivyd (NASDAQ:IVVD) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
In the previous week, Invivyd had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 6 mentions for Invivyd and 2 mentions for Century Therapeutics. Invivyd's average media sentiment score of 1.88 beat Century Therapeutics' score of 0.62 indicating that Century Therapeutics is being referred to more favorably in the news media.
Century Therapeutics has higher revenue and earnings than Invivyd. Century Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
Invivyd has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
70.4% of Invivyd shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 17.9% of Invivyd shares are owned by company insiders. Comparatively, 6.8% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Invivyd currently has a consensus target price of $11.33, suggesting a potential upside of 515.94%. Century Therapeutics has a consensus target price of $13.20, suggesting a potential upside of 327.18%. Given Century Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Invivyd is more favorable than Century Therapeutics.
Invivyd has a net margin of 0.00% compared to Invivyd's net margin of -9,742.41%. Invivyd's return on equity of -59.74% beat Century Therapeutics' return on equity.
Century Therapeutics received 20 more outperform votes than Invivyd when rated by MarketBeat users. However, 66.67% of users gave Invivyd an outperform vote while only 60.87% of users gave Century Therapeutics an outperform vote.
Summary
Invivyd beats Century Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
